United States, Nevada, Las Vegas, DelveInsight’s ‘Dermatomyositis Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Dermatomyositis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dermatomyositis pipeline domain.
Key Takeaways from the Dermatomyositis Pipeline Report
Dermatomyositis Overview
Dermatomyositis is a type of inflammatory myopathy characterized by inflammatory and degenerative changes of the muscles and skin. Associated symptoms and physical findings may vary widely from case to case as patients may present differently. Muscle abnormalities may begin with aches and weakness of the muscles of the trunk, upper arms, hips, and thighs (proximal muscles). Muscles may be stiff, sore, tender and, eventually, show signs of degeneration (atrophy). Dermatomyositis may be diagnosed based upon a detailed patient history, thorough clinical examination, detection of characteristic physical findings, and certain specialized tests. Glucocorticoids, particularly prednisone, are widely used in treating dermatomyositis and are often used first-line. High dose glucocorticoid therapy may produce adverse side effects, particularly after prolonged use, such as a decrease in bone density, causing bones to become brittle and weakened (osteoporosis); increasing, “superimposed” muscle weakness due to effects of the medication (i.e., corticosteroid myopathy); tissue swelling (edema); peptic ulcers; elevated blood pressure; elevated blood sugar levels; weight gain with fat deposits in the abdomen, face, and/or back of the neck or other findings.
Dermatomyositis Pipeline Analysis: Drug Profile
Lenabasum: Corbus Pharmaceuticals
Lenabasum is a novel, oral, small molecule designed to provide an alternative to immunosuppressive treatments for inflammatory or fibrotic diseases. Lenabasum binds to and activates the cannabinoid receptor type 2 (CB2), which is preferentially expressed on activated immune cells, to resolve inflammation and limit fibrosis. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. In clinical testing to date, lenabasum has an acceptable safety and tolerability profiles without evidence of immunosuppression. Lenabasum is currently in phase III stage of development to treat Dermatomyositis.
Discover more about the emerging Dermatomyositis drugs @ Dermatomyositis Treatment Drugs
Dermatomyositis Key Companies
Dermatomyositis Pipeline Therapies
Dermatomyositis Pipeline Therapeutics Assessment
Scope of the Dermatomyositis Pipeline Report
Find out more about the Dermatomyositis treatment options in development @ Dermatomyositis Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Request for a sample report to know more about the leading companies working in the Dermatomyositis Pipeline Segment.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/